The global myasthenia gravis treatment market size is estimated to be USD 1,621.5 million in 2020 and is expected to witness a CAGR of 7.81% during the forecast period. Increasing number of clinical trials for treatment is a key driver for the growth of the global myasthenia gravis treatment market. Additionally, consistent research and development activities, growing investment by various private players, and progress of technologically advanced drugs are some of the other drivers propelling the market growth. Nevertheless, side effects of drugs used in the treatment of myasthenia gravis and high cost of tools and technologies are expected to restrain the global market growth.
Based on treatment, the market is segmented into surgery, medication, and others. In 2020, the medication treatment segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to the fact that medications can radically inhibit the immune system and aid in the management of the associated symptoms. Surgery segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to an increase in the number of patients visiting the hospitals due to the accessibility of a wide range of treatment options in such facilities.
Based on end user, the market is segmented into clinics, hospitals, and others. In 2020, the hospital segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to a large number of patients and high demand for advanced technologies for myasthenia gravis treatment in hospital settings worldwide. The clinics segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to increase in number of patients visiting the clinics of myasthenia gravis due to the availability of a wide range of treatment options in such facilities.
In 2020, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the high rate of adoption of immunotherapies and monoclonal antibodies, increase in healthcare expenditure, and existence of established research and development facilities. Asia Pacific market is projected to grow at the fastest rate over the forecast period owing to the presence of the large population base and future growth opportunities in this region as major pharmaceutical players are willing to invest in this region.Competitor Insights Some of the major companies in the myasthenia gravis treatment market Alexion Pharmaceutical Inc. (U.S.), Grifols SA (Spain), Avadel Pharmaceuticals plc. (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (U.K.), Bausch Health Companies Inc. (Canada), and Shire plc (U.S.). Investment in R&D, novel product launches, and strategic collaborations & acquisitions are some of the major strategies adopted by the leading players operating in the industry.This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The myasthenia gravis treatment market report is categorized into the following segments and subsegments:
By Treatment
Based on treatment, the market is segmented into surgery, medication, and others. In 2020, the medication treatment segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to the fact that medications can radically inhibit the immune system and aid in the management of the associated symptoms. Surgery segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to an increase in the number of patients visiting the hospitals due to the accessibility of a wide range of treatment options in such facilities.
By End User
Based on end user, the market is segmented into clinics, hospitals, and others. In 2020, the hospital segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to a large number of patients and high demand for advanced technologies for myasthenia gravis treatment in hospital settings worldwide. The clinics segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to increase in number of patients visiting the clinics of myasthenia gravis due to the availability of a wide range of treatment options in such facilities.
Regional Insights
In 2020, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the high rate of adoption of immunotherapies and monoclonal antibodies, increase in healthcare expenditure, and existence of established research and development facilities. Asia Pacific market is projected to grow at the fastest rate over the forecast period owing to the presence of the large population base and future growth opportunities in this region as major pharmaceutical players are willing to invest in this region.Competitor Insights Some of the major companies in the myasthenia gravis treatment market Alexion Pharmaceutical Inc. (U.S.), Grifols SA (Spain), Avadel Pharmaceuticals plc. (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (U.K.), Bausch Health Companies Inc. (Canada), and Shire plc (U.S.). Investment in R&D, novel product launches, and strategic collaborations & acquisitions are some of the major strategies adopted by the leading players operating in the industry.This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The myasthenia gravis treatment market report is categorized into the following segments and subsegments:
Myasthenia Gravis Treatment Market, By Treatment (Revenue, 2021-2029, USD Million)
- Surgery Market
- Medication Market
- Others Market
Myasthenia Gravis Treatment Market, By End User (Revenue, 2021-2029, USD Million)
- Clinics Market
- Hospitals Market
- Others Market
Myasthenia Gravis Treatment Market, By Region (Revenue, 2021-2029, USD Million)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
Table of Contents
1. Research Methodology
3. Executive Summary
4. Market Dynamics
5. Market Environment Analysis
6. COVID-19 Impact Analysis: Myasthenia Gravis Treatment Market
7. Market Analysis by Treatment
8. Market Analysis by End User
9. Regional Market Analysis
10. North America Myasthenia Gravis Treatment Market
11. Europe Myasthenia Gravis Treatment Market
12. Asia Pacific Myasthenia Gravis Treatment Market
13. Latin America Myasthenia Gravis Treatment Market
14. MEA Myasthenia Gravis Treatment Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Alexion Pharmaceutical Inc. (U.S.)
- Grifols SA (Spain)
- Avadel Pharmaceuticals plc. (France)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.)
- AbbVie Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- GlaxoSmithKline plc (U.K.)
- Bausch Health Companies Inc. (Canada)
- Shire plc (U.S.)
